市場調查報告書
商品編碼
1308049
靶向蛋白質分解 (TPD) 治療的新興前景Emerging Landscape of Targeted Protein Degradation Therapeutics |
快速的技術進步加強了強大的處理管道
Frost & Sullivan 的研究報告對新興的靶向蛋白質分解 (TPD) 領域進行了深入分析。透過以受控方式攻擊致病蛋白並降低副作用風險,TPD 策略使得治療多種常規方法仍無法治療的疾病成為可能。
據估計,80%的細胞蛋白質組無法透過小分子抑製劑、ASO 和單克隆抗體等傳統方法來靶向,導致了 TPD 方法的發展。事實上,TPD 在過去二十年中已經取得了長足的進步,PROTAC 已成為有史以來研究的最常見的蛋白水解酶。隨著新技術的出現,已經開發了幾種類型的蛋白水解劑。
主要有兩種類型:細胞內分解劑和細胞外分解劑。迄今為止,細胞內蛋白水解劑已得到最廣泛的研究。他們利用泛素蛋白酶體分解途徑來分解細胞內蛋白質,但估計有 40%的編碼細胞外和膜相關蛋白的基因不能被細胞內蛋白水解劑靶向,這導致了細胞外蛋白水解劑的開發。
增加私人和公共資金是推動靶向蛋白質分解技術發展的關鍵因素。本報告包括對 TPD 行業融資趨勢的分析。
本報告討論了細胞外和細胞內蛋白水解劑的類型及其研發重點領域。還分析了不同分解物在不同疾病中的適用性,並確定其臨床應用和相關關鍵參與者。最後,Frost & Sullivan 為 TPD 確定了四個可以改變市場的成長機會。
Rapid Technology Advances Bolster a Robust Therapeutic Pipeline
This Frost & Sullivan research report provides an in-depth analysis of the emerging targeted protein degradation (TPD) space. TPD strategies enable treating various diseases not yet treatable via conventional approaches by attacking disease-causing proteins in a controlled manner, thus reducing the risk of side effects.
It is estimated that 80% of a cell's proteome cannot be targeted via traditional approaches such as small molecule inhibitors, ASO, or monoclonal antibodies, which has led to the development of TPD approaches. Indeed, TPD has advanced enormously in the last two decades, and PROTACs have emerged as the most common protein degrader researched until now. As new technologies emerge, several types of protein degraders have been developed.
Two main types exist: intracellular and extracellular degraders. Until now, intracellular protein degraders have been the most extensively studied. These degrade intracellular proteins by leveraging the ubiquitin-proteasomal degradation pathway, but an estimated 40% of genes encoding extracellular and membrane-associated proteins cannot be targeted by intracellular protein degraders, leading to the development of extracellular protein degradation.
Increased private and public funding is an important factor driving the growth of targeted protein degradation technology. This report includes an analysis of funding trends in the TPD space.
This report discusses the different types of extracellular and intracellular protein degraders and R&D focus areas; it analyses the applicability of different degraders across various diseases and identifies their clinical translation and related key players. Finally, Frost & Sullivan has identified four growth opportunities for TPD that could potentially transform the market.